193 results
Page 6 of 10
8-K
EX-99.1
tnd2o
29 Dec 20
Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
7:29am
8-K
EX-99.1
inxal9cei9d68q
17 Dec 20
Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung Metastases
7:29am
8-K
EX-99.1
bo56p
3 Dec 20
Moleculin To Present Antitumor Activity of Annamycin in Combination with Ara-C in AML at American Society for Hematology Annual Conference
7:29am
8-K
EX-99.1
g6lwt85ncx4mbefg
1 Dec 20
Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for WP1066
4:15pm
8-K
EX-99.1
of4tm
19 Nov 20
Moleculin Announces New Data Demonstrating
4:00pm
8-K
EX-99.1
299 nx9brsdwhl
13 Nov 20
Moleculin Biotech, Inc. Reports Financial Results
7:29am
8-K
EX-99.1
fku4n8 hvble5ep4c8re
29 Oct 20
Moleculin Announces Additional Collaboration on Drug Candidate Targeting COVID-19
7:29am
8-K
EX-99.1
vp3p7oemy ibq
21 Oct 20
Moleculin Announces Independent Study Validates Annamycin’s Ability to Target Lung Localized Tumors, Further Supporting IND
7:29am
8-K
EX-99.1
kefp56
13 Oct 20
Moleculin Announces Additional Positive Interim Results in Adult Glioblastoma Clinical Trial
7:29am
8-K
EX-99.1
nhz f1ou0s8
6 Oct 20
Moleculin Announces New Antiviral Drug
7:29am
8-K
EX-99.1
6y0ocrmq95rwu8jml5
1 Oct 20
Moleculin Announces Positive Interim Results in Pediatric Brain Tumor Phase 1 Clinical Trial at WP1066 demonstrates activity in DIPG, rare form of pediatric brain tumor
7:30am
8-K
EX-99.1
vsmzn93uqmynxremjv3
29 Sep 20
Moleculin Announces Discovery of Significant In Vitro Activity Against COVID-19 Virus for New
7:30am
8-K
EX-99.1
mi1uhm mfe3t2dwe
14 Sep 20
Moleculin Announces COVID-19 In Vivo Testing Contracted for WP1122
4:30pm
8-K
EX-99.1
wj7cpl4xu opq
9 Sep 20
Moleculin Announces Successful Completion of Pre-IND Meeting with the FDA
7:30am
8-K
EX-99.1
9jngm54tg ggq
12 Aug 20
Results of Operations and Financial Condition
7:32am
8-K
EX-99.1
h649j xblps
21 Jul 20
Moleculin Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus
8:41am
8-K
EX-1.1
6j3jj ap4abd5lacp
17 Jul 20
Entry into a Material Definitive Agreement
5:19pm
8-K
EX-99.1
k7280ghri 56b5xs9aoh
15 Jul 20
Moleculin Announces Agreement to Produce WP1122 for Expanded Development of Potential COVID-19 and Oncology Drug Candidate
7:30am